← Browse by Condition
Medical Condition

coronary arterial disease cad

Total Trials
11
Recruiting Now
11
Trial Phases
Phase 4, Phase 2

ClinicalMetric tracks all active clinical trials for coronary arterial disease cad sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — coronary arterial disease cad Clinical Trials

How many clinical trials are currently recruiting for coronary arterial disease cad?
ClinicalMetric currently tracks 11 actively recruiting clinical trials for coronary arterial disease cad, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 11. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for coronary arterial disease cad?
coronary arterial disease cad research spans Phase 2 (1 trial), Phase 4 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a coronary arterial disease cad clinical trial?
Eligibility criteria for coronary arterial disease cad trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Phase 4
3
Top Sponsors
Beijing Anzhen Hospital 1 trial
China National Center for Cardiovascular Diseases 1 trial
Fondazione Toscana Gabriele Monasterio 1 trial
HJN Sverige AB/Neko Health 1 trial
Minneapolis Heart Institute Foundation 1 trial

Recruiting Clinical Trials

NCT06855537 Phase 4
Recruiting
Effectiveness of Interventional Therapy for Non-Flow-Limiting Vulnerable Plaques
Enrollment
2,190 pts
Location
China
Sponsor
Beijing Anzhen Hospital
View Trial →
NCT07041359 Phase 4
Recruiting
Pre-trial of Clinical Trial of Traditional Chinese Medicine Treatment for Elderly Patients With Coronary Heart Disease Who Are Still Symptomatic After Optimal Medical Treatment
Enrollment
120 pts
Location
China
Sponsor
China National Center for Card...
View Trial →
NCT06601153
Recruiting
Health Improvements by Understanding the Determinants of Residual Risk in Coronary Artery Disease and New Targets for Prevention and Treatment
Enrollment
961 pts
Location
Italy
Sponsor
Fondazione Toscana Gabriele Mo...
View Trial →
NCT07001007
Recruiting
SCAPIS 2 Cardio - Vibrometer Based Pulse Wave Analysis and CVD Risk Assessment
Enrollment
1,600 pts
Location
Sweden
Sponsor
HJN Sverige AB/Neko Health
View Trial →
NCT07646444
Recruiting
OPN Balloon for SAFE Recanalization of Calcified Coronary Lesions
Enrollment
300 pts
Location
United States
Sponsor
Minneapolis Heart Institute Fo...
View Trial →
NCT06959524
Recruiting
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
Enrollment
1,616 pts
Location
United States, Austr...
Sponsor
Boston Scientific Corporation
View Trial →
NCT06662500
Recruiting
FORWARD CAD IDE Study
Enrollment
408 pts
Location
United States, Unite...
Sponsor
Shockwave Medical, Inc.
View Trial →
NCT07777341
Recruiting
Study Evaluating the Effects of Red Grape Juice Consumption on Metabolism in Men With Coronary Artery Disease
Enrollment
50 pts
Location
Brazil
Sponsor
University of Sao Paulo Genera...
View Trial →
NCT06866756
Recruiting
Experience in Percutaneous Coronary Intervention With Sirolimus Drug-Coated Balloon and Paclitaxel Drug-Coated Balloon
Enrollment
479 pts
Location
Spain
Sponsor
Andres Iñiguez Romo
View Trial →
NCT07753200 Phase 4
Recruiting
Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease
Enrollment
3,000 pts
Location
South Korea
Sponsor
Samsung Medical Center
View Trial →
NCT07118930 Phase 2
Recruiting
Study of Sivelestat Sodium in OPCABG
Enrollment
62 pts
Location
China
Sponsor
Affiliated Hospital of Nantong...
View Trial →

Related Conditions

vulnerable coronary plaques (1) thin cap fibroatheroma (1) acute coronary syndromes acs (1) arterial stiffness (1) aortic valve disease (1) heart failure (1) in stent restenosis (1) calcified coronary lesions (1) de novo lesions in native coronary arteries (1) atrial fibrillation af (1) coronary heart disease (1) coronary artery disease (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology